| First Posted | New Trial Filing | Phase | Status |
|---|---|---|---|
| 2026-07-31 | NCT07739017 OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT04962126 | Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and… | Follicular Lymphoma | Active, Not Recruiting |
| NCT05788081 | Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/… | Follicular Lymphoma Stage II | Active, Not Recruiting |
| NCT04969887 | Combination Immunotherapy in Rare Cancers Under InvesTigation | Advanced Biliary Tract Cancer | Active, Not Recruiting |
| NCT07634289 | Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell… | Relapsed /Refractory DLBCL | Not Yet Recruiting |
| Phase 1 | |||
| NCT07739017 | OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma | Recurrent Glioblastoma | Not Yet Recruiting |
| Early Phase 1 | |||
| NCT07712770 | Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma | Recurrent Glioblastoma IDH Wildtype | Not Yet Recruiting |